ADC to receive $55M up front & is eligible to receive $50M upon regulatory approval of Zynlonta in 3L DLBCL by EC and ~$330M in additional regulatory & sales milestones along with royalties on net sales of Zynlonta in Sobi’s territories
Sobi will split some of the costs of specific international Zynlonta clinical trials & has a strong worldwide commercial infrastructure along with expertise in haematology & rare diseases
Zynlonta is expected to be available in Q1’23 after a regulatory decision. ADC & MTPC collaborated to develop & commercialize Zynlonta for all hematologic & solid tumors in Japan while ADCT is now conducting a registrational P-II trial of Zynlonta in r/r DLBCL in China under the collaboration with ADC
Ref: Bussinesswire | Image: ADC Therapeutics
